Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flow from operating activities
Net income (loss)	$ 132,330	$ (46,408)	$ (71,197)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation expense	11,153	9,344	11,324
Depreciation	4,441	6,191	5,165
Amortization of premiums and discounts on marketable securities	(3,626)	(16)	349
Gain on lease termination		(2,468)
Change in fair value of common stock and warrants to purchase equity securities			(2,460)
Loss on disposal of fixed assets	178	377
Changes in operating assets and liabilities:
Accounts receivable	(80,150)
Related party collaboration receivable	(3,084)	475	7,280
Prepaid expenses and other assets	76	(1,967)	1,883
Operating lease, right-of-use assets	1,975	3,462	2,606
Other non-current assets		(152)	69
Accounts payable	(962)	1,992	(60)
Accrued expenses	9,007	(3,148)	(3,335)
Operating lease liabilities	(2,833)	(3,922)	(3,428)
Deferred revenue	9,414	23,731	(1,721)
Net cash provided by (used in) operating activities	77,919	(12,509)	(53,525)
Cash flow from investing activities
Purchases of property and equipment	(3,256)	(2,491)	(1,609)
Purchases of marketable securities	(223,968)	(54,848)	(15,117)
Proceeds from sales and maturities of marketable securities	85,581	50,000	82,632
Net cash (used in) provided by investing activities	(141,643)	(7,339)	65,906
Cash flow from financing activities
Proceeds from the exercise of stock options	1,852	629	28
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	31,121
Proceeds from the purchase of common stock under ESPP	672	481	584
Net cash provided by financing activities	33,645	1,110	612
Net (decrease) increase in cash and cash equivalents	(30,079)	(18,738)	12,993
Cash, cash equivalents, and restricted cash beginning of period	100,474	119,212	106,219
Cash, cash equivalents, and restricted cash end of period	$ 70,395	100,474	119,212
Supplemental disclosure of cash and non-cash activities
Operating lease right-of-use assets obtained in exchange for operating lease liabilities			664
Capital expenditures incurred but not yet paid		$ 14	$ 80